HR 9 regulatory risk assessment would add $20 mil. to FDA spending, CBO estimates.
This article was originally published in The Rose Sheet
Executive Summary
REGULATORY RISK ASSESSMENT WOULD ADD ABOUT $20 MIL. TO FDA SPENDING on pre-market regulatory activities each year, the Congressional Budget Office estimates in scoring of the Commerce Committee version of HR 9, the "Job Creation and Wage Enhancement Act," released Feb. 15. The $20 mil. cost is based on "information from FDA," CBO said. Another $17.5 mil. would be added to the cost of rulemaking, FDA maintained. "The agency estimates that the additional analysis required by the bill would add an average of about $700,000 to an additional 25 rules each year," CBO said.